Incyte's Latarcibart Shows Strong Bleed Reduction in Phase 1/2 Trial for Von Willebrand Disease — Incyte

Event summary

Incyte presented Phase 1/2 data for latarcibart at ISTH 2026, showing an 81% median reduction in annualized bleeding rate (ABR) across all von Willebrand disease (VWD) types.
The study involved 16 patients who completed a six-dose regimen of subcutaneous latarcibart administered every four weeks.
Latarcibart demonstrated substantial reductions in ABR, including 75-100% reductions in patients switching from prior VWF-containing prophylaxis.
The treatment was safe and well-tolerated, with only three treatment-emergent adverse events related to latarcibart reported.

The big picture

Incyte's latarcibart represents a significant advancement in treating von Willebrand disease, offering a potential alternative to the frequent IV infusions currently required. The Phase 1/2 data suggests that latarcibart could address a critical unmet need in the hematology space, particularly for patients with all types of VWD. If successful, this therapy could redefine prophylactic care for bleeding disorders and position Incyte as a leader in innovative hematologic treatments.

What we're watching

Regulatory Pathway: Whether the Phase 1/2 data will accelerate regulatory approval for latarcibart, given its Breakthrough Therapy and Fast Track designations.
Market Adoption: The pace at which latarcibart could gain market share if approved, given its potential as a once-monthly subcutaneous therapy compared to current IV infusions.
Clinical Development: How the ongoing Phase 3 VIVID-6 study will validate these findings and whether latarcibart can maintain its efficacy in a larger patient population.